Korolyov

This trial studies bacterial vaginosis in women aged 18 to 45 and evaluates whether combining bovhyaluronidase azoximer with Metronidazole improves treatment outcomes. Bacterial vaginosis involves harmful biofilms mostly formed by Gardnerella vaginalis, which are resistant to treatment and cause frequent relapses. The study aims to see if bovhyaluronidase azoximer can destroy these biofilms, improve treatment effectiveness, and extend relapse-free periods compared to Metronidazole alone. Participants are divided into two groups: one receives Metronidazole plus bovhyaluronidase azoximer vaginal suppositories every other day for 10 days, while the other receives only Metronidazole tablets twice daily for 7 days. Both groups will undergo tests including vaginal acidity measurement, microscopic examination, bacteriologic cultures, PCR, and electron microscopy to assess biofilm presence and treatment effects. Throughout the study, participants will be monitored using Amsel criteria and various laboratory tests to evaluate treatment success and relapse frequency over six months. The main outcome measured is the reduction in bacterial vaginosis relapses six months after treatment. Safety and adherence will also be tracked during this phase 4 clinical trial.